Published in Surgery Litigation and Law Weekly, November 24th, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at YM BioSciences.
Report 1: YM BioSciences Inc. (YMI) announced that its DELEX Therapeutics division has received the results of an interim analysis on the first 67 patients from its randomized, placebo-controlled phase 2b trial (DLXLEF-AP4) of AeroLEF for the treatment of moderate to severe acute pain in post-surgical patients.
The data indicated that AeroLEF provided benefit compared to placebo, however the difference between the treatment arm and placebo arm had not yet achieved the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly